Document is current
Any future updates will be listed below
-
Authors
Glögl, Matthias https://orcid.org/0000-0001-7011-8184
Friedrich, Nikolas https://orcid.org/0000-0003-0694-657X
Cerutti, Gabriele https://orcid.org/0000-0002-9081-7561
Lemmin, Thomas
Kwon, Young D. https://orcid.org/0000-0002-1188-7458
Gorman, Jason https://orcid.org/0000-0002-3775-6560
Maliqi, Liridona
Mittl, Peer R. E. https://orcid.org/0000-0002-3348-3147
Hesselman, Maria C. https://orcid.org/0000-0003-4858-6920
Schmidt, Daniel
Weber, Jacqueline
Foulkes, Caio
Dingens, Adam S.
Bylund, Tatsiana
Olia, Adam S.
Verardi, Raffaello
Reinberg, Thomas
Baumann, Nicolas S.
Rusert, Peter
Dreier, Birgit
Shapiro, Lawrence
Kwong, Peter D. https://orcid.org/0000-0003-3560-232X
Plückthun, Andreas https://orcid.org/0000-0003-4191-5306
Trkola, Alexandra https://orcid.org/0000-0003-1013-876X
- License Information
-
More Information
Article History
Received: 23 September 2022
Accepted: 11 July 2023
First Online: 21 August 2023
Competing interests
: A.P. is a cofounder and shareholder of Molecular Partners AG, who are developing DARPins as therapeutics. A.S.D. is currently an employee of Flagship Labs 77 and may receive a share of IP revenue as an inventor on Fred Hutch-optioned technology/patents related to deep mutational scanning of viral proteins. All other authors declare no competing interests.
